Table 3.

Mean lipid values among 195 HIV-infected children suppressed on ritonavir-boosted lopinavir (LPV/r)-based treatment and randomized to either continue on the LPV/r-based regimen (control group) or to switch to a NVP-based regimen (switch group) at the time of randomization (Time 0R) and at 9, 20 and 31 months post-randomization (PR).

	Control group			Switch group
	N	Mean [standard deviation]		N	Mean [standard deviation]		p-value*
		mmol/l	mg/dL		mmol/l	mg/dL
Total Cholesterol
Time 0R	93	3.79 (1.08)	148 (42.1)	95	3.63 (0.94)	142 (36.6)	>0.10
9 months PR	93	3.89 (0.97)	152 (37.8)	88	4.10 (0.87)	160 (34.0)	>0.10
20 months PR	79	4.44 (0.86)	173 (33.7)	74	4.08 (0.80)	159 (31.1)	0.007
31 months PR	67	4.32 (0.84)	169 (33.0)	55	4.12 (0.77)	161 (30.1)	0.07
Low Density Lipoprotein
Time 0R	93	2.01 (0.91)	78 (35.3)	94	1.94 (0.82)	75 (31.8)	>0.10
9 months PR	93	2.09 (0.79)	81 (31.0)	87	2.20 (0.77)	86 (30.1)	>0.10
20 months PR	72	2.42 (0.84)	94 (32.9)	72	2.20 (0.75)	86 (29.2)	>0.10
31 months PR	67	2.34 (0.80)	91 (31.1)	58	2.23 (0.76)	87 (29.7)	>0.10
High Density Lipoprotein
Time 0R	95	1.03 (0.39)	40 (15.2)	95	1.02 (0.35)	40 (13.7)	>0.10
9 months PR	93	1.09 (0.37)	43 (14.4)	87	1.31 (0.44)	51 (17.1)	0.0006
20 months PR	73	1.24 (0.58)	48 (22.6)	73	1.34 (0.39)	52 (15.2)	0.01
31 months PR	67	1.23 (0.54)	48 (20.9)	58	1.40 (0.48)	54 (18.8)	0.02
TC/HDL ratio
Time 0R	92	4.14 (1.89)		95	3.83 (1.44)		>0.10
9 months PR	93	3.95 (1.77)		87	3.42 (1.22)		0.03
20 months PR	71	3.98 (1.28)		69	3.24 (0.95)		0.0003
31 months PR	64	3.87 (1.46)		55	3.18 (0.89)		0.0096
Triglycerides
Time 0R	95	1.78 (0.93)	158 (82.9)	95	1.52 (0.76)	136 (67.9)	0.05
9 months PR	93	1.56 (0.73)	139 (64.6)	87	1.32 (0.65)	118 (58.1)	0.03
20 months PR	70	1.52 (0.71)	136 (63.2)	73	1.18 (0.65)	105 (58.2)	0.0009
31 months PR	68	1.49 (0.71)	133 (63.2)	57	1.04 (0.59)	93 (52.7)	<0.0001

^*Groups are compared using Wilcoxon rank-sum tests